Tractatenblad van het Koninkrijk der Nederlanden
Datum publicatie | Organisatie | Jaargang en nummer | Rubriek | Datum totstandkoming |
---|---|---|---|---|
Ministerie van Buitenlandse Zaken | Tractatenblad 2015, 87 | Verdrag |
Zoals vergunningen, bouwplannen en lokale regelgeving.
Adressen en contactpersonen van overheidsorganisaties.
U bent hier:
Datum publicatie | Organisatie | Jaargang en nummer | Rubriek | Datum totstandkoming |
---|---|---|---|---|
Ministerie van Buitenlandse Zaken | Tractatenblad 2015, 87 | Verdrag |
66 (1989) Nr. 21
Overeenkomst ter bestrijding van doping;
(met Bijlage)
Straatsburg, 16 november 1989
De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in Trb. 1991, 8.
Voor correcties, zie Trb. 2014, 162.
In Trb. 1991, 8 dienen in de Engelse tekst opnieuw de volgende correcties te worden aangebracht.
Op blz. 2, in de preambule, negende alinea, laatste regel, dient de zinsnede „in Reykjavik” te worden vervangen door „at Reykjavik”.
Op blz. 6, in artikel 4, eerste lid, laatste regel, dient het woord „steriods” te worden vervangen door „steroids”.
Op blz. 10, in artikel 6, tweede lid, eerste regel, dient de zinsnede „undertake the encourage” te worden vervangen door „undertake to encourage”.
Op blz. 20, in artikel 16, eerste lid, vijfde regel, dient het woord „Statue” te worden vervangen door „Statute”.
Voor wijzigingen van de tekst van de Bijlage, zie rubriek J van Trb. 1995, 114, Trb. 1996, 284, Trb. 1997, 44, Trb. 1997, 244, Trb. 1998, 104, Trb. 2001, 98, Trb. 2001, 185, Trb. 2003, 40, Trb. 2004, 194 en rubriek B van Trb. 2005, 67, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 19, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21 en Trb. 2014, 162.
Voor enkele correcties, zie Trb. 2008, 83 en Trb. 2009, 24.
De Commissie van Toezicht heeft tijdens haar 41ste Vergadering op 5 november 2014, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst1) van de wijziging luidt als volgt:
World Anti-Doping Code
Date of entry into force: 1 January 2015
In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S.4.4, S.4.5, S6.a, and Prohibited Methods M1, M2 and M3.
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)
a. Exogenous1) AAS, including:
1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α-androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19- norpregna-4-en-17α-ol); fluoxymesterone; formebolone; furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one); trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous2) AAS when administered exogenously:
Androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA, 3β- hydroxyandrost-5-en-17-one); testosterone;
and their metabolites and isomers, including but not limited to:
5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane-3β,17β-diol; 5β-androstane-3α,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol;
androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α -diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3,17-dione); androsterone (3β-hydroxy-5α-androstan-17-one); epi-dihydrotestosterone; epitestosterone; etiocholanolone; 7 α -hydroxy-DHEA; 7 β -hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone.
2. Other Anabolic Agents, including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeranol and zilpaterol.
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
1. Erythropoietin-Receptor agonists:
1.1. Erythropoiesis-Stimulating Agents (ESAs) including e.g. darbepoietin (dEPO); erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; and methoxy polyethylene glycol-epoetin beta (CERA);
1.2. Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290, asialo EPO and carbamylated EPO;
2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon;
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males;
4. Corticotrophins and their releasing factors, e.g corticorelin;
5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH- Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2).
Additional prohibited growth factors:
Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Except:
• Inhaled salbutamol (maximum 1600 micrograms over 24 hours);
• Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
• Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: aminoglutethimide; anastrozole; androsta- 1,4,6-triene-3,17-dione (androstatrienedione); 4-androstene-3,6,17 trione (6-oxo); exemestane;
formestane; letrozole and testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene;
tamoxifen and toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene; cyclofenil and fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.
5. Metabolic modulators:
5.1. Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome
Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516;
5.2. Insulins;
5.3. Trimetazidine.
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
Including, but not limited to:
• Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
• Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid;
furosemide; indapamide; metolazone; spironolactone; thiazides, e.g.
bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.
Except:
• Drospirenone; pamabrom; and topical dorzolamide and brinzolamide.
• Local administration of felypressin in dental anaesthesia.
The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent.
The following are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during
Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.
The following, with the potential to enhance sport performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.
In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition:
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include:
a: Non-Specified Stimulants:
Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine(d-); p-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phentermine; prenylamine and prolintane.
A stimulant not expressly listed in this section is a Specified Substance.
b: Specified Stimulants.
Including, but not limited to:
Benzfetamine; cathine 3); cathinone and its analogues, e.g. mephedrone, methedrone, and α-pyrrolidinovalerophenone; dimethylamphetamine; ephedrine 4) ; epinephrine 5) (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroxyamphetamine); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxymethamphetamine; methylephedrine6) ; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); pemoline;
pentetrazol; phenethylamine and its derivatives; phenmetrazine; phenpromethamine; propylhexedrine; pseudoephedrine 7) ; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine), tuaminoheptane;
and other substances with a similar chemical structure or similar biological effect(s).
Except:
Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2015 Monitoring
Program8).
Prohibited:
Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine; oxycodone; oxymorphone; pentazocine and pethidine.
Prohibited:
• Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC).
• Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.
• Air Sports (FAI)
• Archery (WA)
• Automobile (FIA)
• Motorcycling (FIM)
• Powerboating (UIM)
Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.
• Archery (WA)9)
• Automobile (FIA)
• Billiards (all disciplines) (WCBS)
• Darts (WDF)
• Golf (IGF)
• Shooting (ISSF, IPC)10)
• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
• Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea.
Including, but not limited to:
Acebutolol; alprenolol; atenolol; betaxolol; bisoprolol; bunolol; carteolol; carvedilol; celiprolol; esmolol; labetalol; levobunolol; metipranolol; metoprolol; nadolol; oxprenolol; pindolol; propranolol; sotalol and timolol.
Zie Trb. 1991, 8.
Voor correcties, zie Trb. 2014, 162.
Zie Trb. 1995, 114.
Zie Trb. 1991, 8, rubriek F en rubriek H van Trb. 1995, 114 en, laatstelijk, Trb. 2014, 21.
Zie Trb. 1991, 8, Trb. 1995, 114, rubriek J van Trb. 1996, 284, Trb. 1997, 244, Trb. 1998, 104, Trb. 2001, 98, Trb. 2001, 185, Trb. 2003, 40 en Trb. 2004, 194, en rubriek G van Trb. 2005, 67, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 19, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21 en Trb. 2014, 162.
De wijziging van 5 november 2014 van de Bijlage bij de Overeenkomst is op 1 januari 2015 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.
Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten.
Land |
Voorlopige toepassing |
In werking |
Terugwerkende kracht |
Buiten werking |
---|---|---|---|---|
Nederland (in Europa) |
01-06-1995 |
|||
Nederland (Bonaire) |
10-10-2010 |
|||
Nederland (Sint Eustatius) |
10-10-2010 |
|||
Nederland (Saba) |
10-10-2010 |
|||
Aruba |
||||
Curaçao |
10-10-2010 |
|||
Sint Maarten |
10-10-2010 |
|||
De Overeenkomst, met Bijlage, gold sinds 01-01-2009 voor de Nederlandse Antillen. |
Zie Trb. 1991, 8, Trb. 1995, 114, Trb. 1996, 284, Trb. 1997, 44, Trb. 2004, 194, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21 en Trb. 2014, 162.
Titel |
: |
Internationaal Verdrag tegen doping in de sport; Parijs, 19 oktober 2005 |
Laatste Trb. |
: |
In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 5 november 2014 van de Bijlage zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.
Uitgegeven de elfde juni 2015.
De Minister van Buitenlandse Zaken, A.G. KOENDERS
Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.
Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.
Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.
Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2015 Monitoring Program, and are not considered Prohibited Substances.
Kopieer de link naar uw clipboard
https://zoek.officielebekendmakingen.nl/trb-2015-87.html
De hier aangeboden pdf-bestanden van het Staatsblad, Staatscourant, Tractatenblad, provinciaal blad, gemeenteblad, waterschapsblad en blad gemeenschappelijke regeling vormen de formele bekendmakingen in de zin van de Bekendmakingswet en de Rijkswet goedkeuring en bekendmaking verdragen voor zover ze na 1 juli 2009 zijn uitgegeven. Voor pdf-publicaties van vóór deze datum geldt dat alleen de in papieren vorm uitgegeven bladen formele status hebben; de hier aangeboden elektronische versies daarvan worden bij wijze van service aangeboden.